Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with a type of blood cancer called AML (acute myeloid leukaemia), where at least 20% of bone marrow cells are abnormal blast cells, but not the specific subtype called APL (acute promyelocytic leukaemia)
• People whose AML has a specific gene change called a FLT3 mutation, detected at the time of first diagnosis
• People whose doctor has determined that standard intensive chemotherapy is not suitable for them
• People who have already received one cycle of a standard treatment combination of two drugs called Venetoclax and Azacitidine before joining the trial

Who may not be able to join:

• People whose AML has come back after treatment or has stopped responding to treatment (known as relapsed or refractory AML)
• People who have previously received any treatment for AML, other than a drug called hydroxyurea and/or one cycle of Venetoclax and Azacitidine as standard care
• People who have previously been treated with a drug called Gilteritinib
• People who have active involvement of the brain or spinal cord by their leukaemia
• People who have a specific heart electrical abnormality detected at screening, including a prolonged QTcF interval (above 450 ms) or a condition called Long QT Syndrome (confirm with trial site)
• People who are currently taking certain strong medications that affect how the body processes drugs, or who are taking a herbal supplement called St. John's Wort

Important: Always verify eligibility with the trial site directly before applying.